Strong October for GenMark, Myriad Stocks Lead GWDN Index Rise | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of GenMark Diagnostics and Myriad Genetics rose more than 20 percent each in October, to lead the 34 stocks that comprise the GenomeWeb Daily News Index.

Overall, the Index gained 5 percent — less than the Nasdaq, which was up 6 percent for October, but outperforming the Nasdaq Biotech Index, which rose nearly 4 percent, and the Dow Jones Industrial Average, which gained 3 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.